| 1 | Biologic DMARD | - | - | - | - | 2件: 46 46, 271 💬 |
| 2 | Biologic DMARDs | - | - | - | - | 1件: 107 107 💬 |
| 3 | Biological DMARDs | - | - | - | - | 2件: 86 86, 107 💬 |
| 4 | Classic DMARDs treatment group | - | - | - | - | 1件: 46 46 💬 |
| 5 | Co-medication: Synthetic DMARDs | - | - | - | - | 1件: 46 46 💬 |
| 6 | Combination of DMARDs | - | - | - | - | 1件: 107 107 💬 |
| 7 | Conventional DMARD combination | - | - | - | - | 1件: 46 46 💬 |
| 8 | Conventional DMARDs | - | - | - | - | 1件: 46 46 💬 |
| 9 | Conventional Synthetic DMARD | - | - | - | - | 1件: 46 46 💬 |
| 10 | Disease-modifying antirheumatic drugs (DMARDs) | - | - | - | - | 1件: 46 46 💬 |
| 11 | DMARD | - | - | - | - | 1件: 46 46 💬 |
| 12 | DMARD cessation | - | - | - | - | 1件: 46 46 💬 |
| 13 | DMARD maintenance | - | - | - | - | 1件: 46 46 💬 |
| 14 | DMARD Therapy | - | - | - | - | 1件: 46 46 💬 |
| 15 | DMARDS | - | - | - | - | 2件: 46 46, 271 💬 |
| 16 | DMARDs (disease-modifying antirheumatic drugs) | - | - | - | - | 1件: 46 46 💬 |
| 17 | DMARDs (methotrexate | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR,
DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
| 18 | DMARDs or Biologics | - | - | - | - | 1件: 46 46 💬 |
| 19 | Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA,
TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
| 20 | HUC-MSC + DMARDs | - | - | - | - | 1件: 46 46 💬 |
| 21 | Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | - | - | - | - | 1件: 46 46 💬 |
| 22 | Non-Biologic DMARDs | - | - | - | - | 3件: 46 46, 86, 107 💬 |
| 23 | Non-biological DMARDs | - | - | - | - | 1件: 46 46 💬 |
| 24 | Nonbiologic DMARDs of investigator's choice | - | - | - | - | 1件: 46 46 💬 |
| 25 | Patient treated with DMARD | - | - | - | - | 1件: 46 46 💬 |
| 26 | Permitted DMARDs | - | - | - | - | 1件: 46 46 💬 |
| 27 | Phase 1: Conventiaonal DMARD | - | - | - | - | 1件: 46 46 💬 |
| 28 | Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) | - | - | - | - | 1件: 46 46 💬 |
| 29 | Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | - | - | - | - | 1件: 46 46 💬 |
| 30 | Synthetic DMARD(s) | - | - | - | - | 1件: 46 46 💬 |
| 31 | Targeted synthetic DMARD class | - | - | - | - | 1件: 46 46 💬 |
| 32 | Therapy with disease-modifying anti rheumatic drugs (DMARD) | - | - | - | - | 1件: 46 46 💬 |
| 33 | TNF-a antagonists, non-TNFs, DMARD non-biologics | - | - | - | - | 2件: 46 46, 271 💬 |
| 34 | Trivalent chromium versus synthetic and/ or biological DMARDs | 1件: Chromium Chromium | - | - | - | 1件: 46 46 💬 |
| 35 | UC-MSC+DMARDS | - | - | - | - | 1件: 46 46 💬 |